CervoMed news
- Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process
- Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital
- LifeSci-affiliated Fund Commences Proxy Contest for Control of the Diffusion Board Following Rejection of Client’s Offer
- Company Believes LifeSci Proxy Campaign is Attempt to Cir
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, will participate in the 2021 Alliance Global Partners Biotech & Specialty Pharma Conference taking place November 10, 2021. Diffusion will also be participating in one-on-
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that its Board of Directors (the “Board”) has authorized a thorough review and evaluation of a range of potential strategic opportunities in the interest of enhancing stockholder value including transactional opportuni
- Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”) patients
- Company to evaluate effects of TSC on tumor oxygenation using an innovative positron emission tomography (“PET”) hypoxia imaging methodology with data expected within one year of study initiation
- Diffusion previously obtained Orphan
- Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval
- Positive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise interval
- TSC was safe and well-tolerated by all subjects with no serious adverse events reported